Cargando…
Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680337/ https://www.ncbi.nlm.nih.gov/pubmed/36412836 http://dx.doi.org/10.3390/antib11040070 |
_version_ | 1784834393135644672 |
---|---|
author | Lau, Chin Shern Thundyil, John Oh, May Lin Helen Phua, Soon Kieng Liang, Ya Li Li, Yanfeng Huo, Jianxin Huang, Yuhan Zhang, Biyan Xu, Shengli Aw, Tar Choon |
author_facet | Lau, Chin Shern Thundyil, John Oh, May Lin Helen Phua, Soon Kieng Liang, Ya Li Li, Yanfeng Huo, Jianxin Huang, Yuhan Zhang, Biyan Xu, Shengli Aw, Tar Choon |
author_sort | Lau, Chin Shern |
collection | PubMed |
description | Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab (Roche), IgG (Abbott) and N-Ab (Snibe) levels at set time points from January 2021 to April 2022. All subjects were deemed to be COVID-19-naïve either via clinical history (CoronaVac vaccinees) or nucleocapsid antibody testing (BNT162b2 vaccinees). Results: All antibodies peaked 20–30 days post-inoculation. In BNT162b2 vaccinees, all post-booster antibodies were significantly higher than second-dose peaks. In CoronaVac vaccinees, IgG showed no significant differences between peak third-/second-dose titers (difference of 56.0 BAU/mL, 95% CI of −17.1 to 129, p = 0.0894). The post-vaccination titers of all antibodies in BNT162b2 vaccinees were significantly higher than those in CoronaVac vaccinees at all time points. Post-booster, all antibodies declined in 90 days; the final total/IgG/N-Ab titers were 7536 BAU/mL, 1276 BAU/mL and 12.5 μg/mL in BNT162b2 vaccinees and 646 BAU/mL, 62.4 BAU/mL and 0.44 μg/mL in CoronaVac vaccinees. Conclusion: The mRNA vaccine generated more robust total S-Ab, IgG and N-Ab responses after the second and third vaccinations. |
format | Online Article Text |
id | pubmed-9680337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96803372022-11-23 Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster Lau, Chin Shern Thundyil, John Oh, May Lin Helen Phua, Soon Kieng Liang, Ya Li Li, Yanfeng Huo, Jianxin Huang, Yuhan Zhang, Biyan Xu, Shengli Aw, Tar Choon Antibodies (Basel) Article Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab (Roche), IgG (Abbott) and N-Ab (Snibe) levels at set time points from January 2021 to April 2022. All subjects were deemed to be COVID-19-naïve either via clinical history (CoronaVac vaccinees) or nucleocapsid antibody testing (BNT162b2 vaccinees). Results: All antibodies peaked 20–30 days post-inoculation. In BNT162b2 vaccinees, all post-booster antibodies were significantly higher than second-dose peaks. In CoronaVac vaccinees, IgG showed no significant differences between peak third-/second-dose titers (difference of 56.0 BAU/mL, 95% CI of −17.1 to 129, p = 0.0894). The post-vaccination titers of all antibodies in BNT162b2 vaccinees were significantly higher than those in CoronaVac vaccinees at all time points. Post-booster, all antibodies declined in 90 days; the final total/IgG/N-Ab titers were 7536 BAU/mL, 1276 BAU/mL and 12.5 μg/mL in BNT162b2 vaccinees and 646 BAU/mL, 62.4 BAU/mL and 0.44 μg/mL in CoronaVac vaccinees. Conclusion: The mRNA vaccine generated more robust total S-Ab, IgG and N-Ab responses after the second and third vaccinations. MDPI 2022-11-08 /pmc/articles/PMC9680337/ /pubmed/36412836 http://dx.doi.org/10.3390/antib11040070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lau, Chin Shern Thundyil, John Oh, May Lin Helen Phua, Soon Kieng Liang, Ya Li Li, Yanfeng Huo, Jianxin Huang, Yuhan Zhang, Biyan Xu, Shengli Aw, Tar Choon Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster |
title | Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster |
title_full | Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster |
title_fullStr | Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster |
title_full_unstemmed | Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster |
title_short | Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster |
title_sort | neutralizing and total/igg spike antibody responses following homologous coronavac vs. bnt162b2 vaccination up to 90 days post-booster |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680337/ https://www.ncbi.nlm.nih.gov/pubmed/36412836 http://dx.doi.org/10.3390/antib11040070 |
work_keys_str_mv | AT lauchinshern neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT thundyiljohn neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT ohmaylinhelen neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT phuasoonkieng neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT liangyali neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT liyanfeng neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT huojianxin neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT huangyuhan neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT zhangbiyan neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT xushengli neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster AT awtarchoon neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster |